Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments
JPGN Reports · 2024-11 · 5 (4) · 447-453
DOI: 10.1002/jpr3.12124 ↗Kurz gefasst
Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 05.09.2024. Verfasst von Andrew Dickerson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Gastroenterology University of California San Diego California USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMHD NIH HHS.
Abstract (Originalsprache)
Objectives
Upadacitinib (UPA), a selective Janus kinase‐1 inhibitor, has demonstrated efficacy in inducing and maintaining remission in moderate to severe ulcerative colitis (UC) in adults. Current standard management for acute severe ulcerative colitis (ASUC) involves intravenous corticosteroids (IVCS) followed by infliximab (IFX) salvage therapy. Limited data exist on the utility of UPA in ASUC, particularly in adolescents. This case series reports the use of UPA as salvage therapy in hospitalized adolescents experiencing ASUC refractory to IFX.
Methods
We performed a retrospective chart review of hospitalized patients with ASUC who received UPA as salvage therapy after initiation of IVCS and failure of IFX.
Results
Three adolescents were hospitalized with ASUC for which IFX infusion treatments were unsuccessful. Initiation of UPA enabled patients to improve their Pediatric Ulcerative Colitis Activity Index scores to ≤35 and be discharged home. Hospitalization course, complications, and follow‐up information are provided.
Conclusion
UPA is a promising short‐term salvage therapy in adolescent ASUC cases resistant to conventional treatments. Prospective studies are warranted to elucidate its long‐term efficacy and safety in this specific population. These findings provide a novel therapeutic avenue for managing ASUC in adolescents, offering hope for those encountering treatment challenges.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Gastroenterology University of California San Diego California USA.
- Rady Children's Hospital San Diego California USA.
ORCID-Profile: Laura E Bauman
Förderung
- NIMHD NIH HHS
Zitieren
APA
Dickerson, A., Huang, J. S., & Bauman, L. E. (2024). Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Reports, 5(4), 447-453. https://doi.org/10.1002/jpr3.12124
Vancouver
Dickerson A, Huang JS, Bauman LE. Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Reports. 2024;5(4):447-453. doi:10.1002/jpr3.12124
BibTeX
@article{Dickerson2024,
author = {Dickerson, Andrew and Huang, Jeannie S and Bauman, Laura E},
title = {Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments},
journal = {JPGN Reports},
year = {2024},
volume = {5},
number = {4},
pages = {447--453},
doi = {10.1002/jpr3.12124}
}
EUVIMED